Tag Archives: Pandemic

U.S. budget airlines plot pandemic breakthrough

By Tracy Rucinski

PALM COAST, Fla. (Reuters) – The COVID-19 pandemic has reshaped the global travel landscape and U.S. no-frills carriers are pouncing.

As legacy airlines shrink to contain costs, budget carriers Spirit Airlines, Allegiant Travel and privately-owned Frontier Airlines are resuming pilot hiring and expanding networks to seize turf dominated by larger rivals.

The three airlines’ combined U.S. market share, which barely topped 10% before the pandemic, could grow by 10 percentage points this year alone, said René Armas Maes of UK-based consultancy MIDAS Aviation.

“Ultra low-cost carriers want to attack head-to-head; they believe they’re in a better position to rebuild travel demand,” he said.

Las Vegas-based Allegiant has told prospective pilots whose hiring was halted as the pandemic unfolded: “We have recalled all of our furloughed pilots and are now planning for exciting growth opportunities.”

Spirit and Frontier have posted pilot job ads and are taking delivery of Airbus A320neo jets that could open longer routes, including coast-to-coast flying traditionally controlled by legacy, or full-service, carriers.

By contrast, American Airlines has gone from hiring 100 pilots a month before the pandemic to threatening 1,850 furloughs without fresh government assistance on labor costs.

Allegiant also stands to benefit if Congress approves a third round of COVID-19 payroll relief for U.S. airlines, but “would be just fine without it,” Chief Financial Officer Greg Anderson told Reuters.

“The leading indicators suggest that there is a nice growth trajectory for Allegiant,” said Anderson, citing Google searches, indices that track changes in city populations and infection and vaccination trends from the Institute for Health Metrics and Evaluation.

He said customer surveys also show an increased preference for smaller airports and non-stop flights, cornerstones of budget carriers’ business models.

TRIAL AND ERROR

Ultra low-cost carriers, or ULCCs, offer a no-frills experience at rock-bottom fares and charge heavily for extras like bags. They wage fare wars and are pervasive in Europe’s fragmented market but have lagged in the United States.

ULCCs are a tier below carriers like Southwest Airlines, which pioneered the low-cost concept in the 1970’s and has grown to become the leading domestic airline. It provides free beverages and checked bags but keeps costs low in part by flying a single fleet-type of Boeing 737’s.

U.S. mainline legacy carriers American, Delta Air Lines and United Airlines have diverse fleets that include expensive wide-body jets geared for the kind of business and international travel that has suffered most in the pandemic.

American’s unit costs excluding fuel, a key metric of efficiency, were $0.18 per available mile in 2020, more than double that of budget rivals like Allegiant, according to data compiled by financial services firm Raymond James.

This means Allegiant, which primarily uses second-hand planes and only flies on peak travel days like weekends, can more easily profit on discount fares.

And whereas legacy carriers use a hub-and-spoke network that shuttles people through costly big-city airports, the ULCC business model is based on point-to-point travel to smaller airports where they outsource much of their infrastructure.

Allegiant’s fixed costs account for just around a quarter of its total.

That flexibility helps budget carriers open new routes on a trial-and-error basis. During the pandemic, for example, they have pivoted toward beach and mountain destinations.

“Then if the route is not performing, they won’t hesitate to shut it down,” said George Dimitroff of consultants Ascend by Cirium.

But there are risks.

American, United and Delta have also shifted flights during the pandemic to pick up leisure demand and their market power and geographical reach remain formidable.

Competing with them can lure upstart airlines into relaxing cost discipline – a move described as a “path to hell” by budget airlines entrepreneur Bill Franke, who championed the ULCC model.

Together the three large airlines control around 60% of domestic travel and could chase away rivals on smaller routes if they choose, industry critics said.

But they are more burdened by debt than the ULCCs and continue to burn through millions of dollars every day, hampering their ability to grow, the critics said.

BUDGET SHIFT

Beyond low fares, experts said the pandemic has given budget carriers a fresh argument for previously wary customers.

Traditional airline perks like catering services have lost their luster in an era of masks, and budget airplanes feature the same hospital-grade aircraft filtration systems as others.

And they could benefit from more cost-conscious small and medium sized businesses changing travel policies to favor lower-cost airlines, albeit constrained by their more limited flying through large hubs.

“More price-sensitive travel will be the new normal for the next couple of years at least,” Armas Maes said.

Even so, today’s outsiders will face a competitive cycle.

After the last downturn, low-cost carrier JetBlue Airways grabbed market share from American on the U.S. east coast. Now it is grappling with competition from ULCCs and is teaming up with its old rival.

(Reporting by Tracy Rucinski; editing by Barbara Lewis and Nick Zieminski)

COVAX vaccine program to deliver 237 million doses to 142 nations by end-May

GENEVA/LONDON (Reuters) – The COVAX vaccine-sharing program said on Tuesday it will deliver 237 million doses of AstraZeneca’s COVID-19 shot to 142 countries by the end of May as it steps up the global roll-out of its vaccine supplies.

The timeline for the delivery of doses, made by AstraZeneca and by India’s Serum Institute, will be split into separate two-month schedules, COVAX said in a statement, with the first in February-March and the second in April-May.

“These timelines are dependent on a variety of factors including national regulatory requirements, availability of supply, and fulfillment of other criteria such as validated national deployment and vaccination plans,” the statement said.

COVAX is the World Health Organization-backed program to provide vaccines for poor and middle-income countries. It began its roll-out last week with the first deliveries of shots to Ghana and Ivory Coast.

Hailing the campaign as an “unprecedented partnership,” WHO Director-General Tedros Adhanom Ghebreyesus said Angola, Cambodia, Democratic Republic of Congo and Nigeria could also expect deliveries of COVAX-supplied vaccines on Tuesday.

“This is an unprecedented partnership that will not only change the course of the pandemic but also change the way the world responds to future health emergencies,” Tedros told a joint media briefing with the U.N. Children’s Fund UNICEF, the GAVI vaccines alliance – which co-leads COVAX – and others.

Ghanaian President Nana Akufo-Addo told the same briefing that his West African country, which this week began its inoculation campaign with COVAX doses, aimed to vaccinate 20 million people by the end of 2021.

COVAX added in a statement that as well as the first round of allocations of the AstraZeneca vaccine, some 1.2 million doses of the Pfizer-BioNTech COVID shot were also anticipated for delivery in the first quarter of 2021.

(Reporting by Emma Farge and Stephanie Nebehay in Geneva and Kate Kelland in London; Editing by Mark Heinrich)

U.S. to give Americans COVID-19 vaccines before discussing sharing with Mexico: White House

By Steve Holland and Dave Graham

WASHINGTON/MEXICO CITY (Reuters) – The Biden administration on Monday downplayed the prospect of sharing coronavirus vaccines with Mexico, saying it is focused first on getting its own population protected against a pandemic that has killed more than 500,000 Americans.

The remarks by White House press secretary Jen Psaki came hours before Mexican President Andres Manuel Lopez Obrador is expected to ask U.S. President Joe Biden to consider sharing some of its COVID-19 vaccine supply.

“The administration’s focus is on ensuring that every American is vaccinated. And once we accomplish that objective we’re happy to discuss further steps,” Psaki said at a White House news conference.

The two leaders are due to hold a virtual meeting later on Monday that is also likely to encompass immigration and trade.

Biden has predicted the United States will have enough supply by late July to inoculate all Americans. U.S. authorities have administered 76.9 million doses to date, according to the U.S. Centers for Disease Control and Prevention, enough for 23% of the population to get the two doses recommended for full protection under the vaccines that have been deployed so far.

Mexico has vaccinated roughly 2.5 million doses so far, enough for about 1% of the population, according to data compiled by Reuters. Officials have been frustrated by bottlenecks in supply and raised concerns that wealthy countries are hoarding vaccines.

According to Reuters reporting, Mexico would aim to pay back Washington once pharmaceutical companies have delivered on their orders.

Mexican magazine Proceso said Lopez Obrador had asked Biden for help on vaccines in January.

“We’d like to get an answer on a request that we’ve already made … about the vaccines,” Lopez Obrador told a regular news conference on Monday. “Provided he’s of the view the matter should be addressed. We must be respectful.”

IMMIGRATION AND ENERGY

Immigration, security, climate change and the United States-Mexico-Canada Agreement (USMCA) trade deal were also likely to feature in talks, said Lopez Obrador, a left-wing nationalist.

Mindful of pressure to curb unlawful immigration, Lopez Obrador said on Saturday he wants Biden to help secure U.S. work permits for Mexicans and Central Americans, saying the United States needed another 600,000-800,000 workers.

On Monday, Lopez Obrador said he wanted to broker an agreement that covered all kinds of workers, including “professionals.”

The two leaders could also discuss Lopez Obrador’s efforts to strengthen a state-run electricity utility, the Comision Federal de Electricidad (CFE).

The Mexican president has cast the legislation as a matter of national sovereignty, arguing that past governments skewed the electricity market in favor of private operators.

Business groups have condemned the bill, saying it risks violating the USMCA and endangers Mexico’s renewable energy targets because it puts wind and solar generators at a disadvantage against the CFE, a heavy user of fossil fuels.

(Reporting by Dave Graham, Steve Holland and Alexandra Alper; Additional reporting by Nandita Bose and David Alire Garcia; Writing by Andy Sullivan; Editing by Giles Elgood and Aurora Ellis)

As pandemic eases elsewhere, some Caribbean states face worst outbreaks yet

By Kate Chappell and Sarah Marsh

KINGSTON (Reuters) – In Jamaica, which won praise for containing its coronavirus outbreak last year, patients now overflow into corridors on chairs and stretchers in some hospitals, prompting the Caribbean nation to open three emergency field hospitals.

While global new infections start to decline, a handful of countries across the Caribbean, including the larger islands of Jamaica and Cuba, are suffering their worst outbreaks since the start of the pandemic following social gatherings over year-end, quarantine violations by visitors and growing complacency.

The number of total confirmed cases has almost doubled in the first two months of the year in Jamaica. It has risen around fourfold in Cuba, eightfold in Barbados and around tenfold in St. Lucia and St. Vincent and the Grenadines, according to Oxford University’s Our World in Data database.

In one of the most tourism-dependent regions of the world, authorities have had to reimpose lockdowns and curfews, while reducing flights and hiking quarantine restrictions, further delaying a revival of their fragile economies.

Some Caribbean nations have started inoculating citizens – thanks, in particular, to an Indian donation of the AstraZeneca vaccine – yet broad coverage still looks far off. Cuba is launching late phase trials of two of its own vaccine candidates this month.

“Once the capacity of the health system becomes threatened, we could see a spike not only in the numbers infected but also in those dying from the disease,” Jamaican Prime Minister Andrew Holness warned in a broadcast address to the nation on Sunday.

The effect of COVID-19 in Caribbean countries has been mixed. In Jamaica, deaths have risen 1.4 times since the end of the year and now stand at 422. Cuba’s death toll of 324 is well under the world average per capital – a statistic the government largely puts down to a good healthcare system and experimental treatments – but the number of deaths has doubled there so far in 2021.

Tiny St Vincent and Grenadines registered its first COVID-19 death this year and has now had eight fatal victims.

While most of the Caribbean islands still have adequate hospital capacity to deal with the crisis, in Jamaica, all beds dedicated to COVID-19 isolation were full as of Feb. 26, according to the health ministry.

Holness announced more capacity was being added and lockdown restrictions tightened, including a new stay-at-home order for those aged 60 and above and a ban on access to beaches.

“We are not coping. We are physically and emotionally drained,” said a nurse who did not want to be named for fear of losing her job.

SLOW VACCINE ROLLOUT

Caribbean leaders have complained about difficulty accessing vaccines and hoarding by rich nations amid a slow rollout of vaccines by the United Nations-backed COVAX alliance created to ensure poor countries across the world are not left behind.

Jamaica, which has nearly 3 million inhabitants, will receive a donation from India of 50,000 vaccine doses on or before Thursday, Health minister Christopher Tufton said on Sunday at the briefing alongside Holness.

The island nation should also start receiving its 124,800 doses via the COVAX facility this month, and 1.8 million via the African Medical Supply Platform from April.

But depending on which vaccine is secured, Jamaica still needed to source up to an extra 1.5 million doses to fulfill its aim of inoculating at least 65 % of the population by March 2022, Tufton said.

The prospects for an immediate economic recovery in the face of a slow vaccine roll-out are dim, said Therese Turner-Jones, general manager of the Caribbean Country Department for the Inter-American Development Bank.

“It’s going to be another difficult two years ahead,” Turner-Jones said. “Absent a healthy environment, there is not much you are going to do that will get back to business as usual.”

The Caribbean Development Bank said last Thursday it projected growth of 3.8% in its 19 borrowing member countries this year after a contraction of 12.8% last year, with vaccine availability one risk to that forecast.

Still, Cuba could hold a ray of light. It already came through for the Caribbean in terms of sending doctors to neighboring islands throughout the pandemic.

Now, the regional biotech heavyweight says it is already mass producing two of its four vaccine candidates in order to launch late phase trials in March.

Should its vaccine candidates triumph – becoming the first Latin American homegrown COVID vaccines to be approved – then its neighbors and regional allies could benefit.

(Reporting by Kate Chappell in Kingston; Additional Reporting by Sarah Marsh in Chester, UK, and Rob Edison Sandiford in Bridgetown; Editing by Alistair Bell)

G20 to show united front on support for global economic recovery, cash for IMF

By Michael Nienaber and Andrea Shalal

BERLIN/WASHINGTON/ROME (Reuters) – The world’s financial leaders are expected on Friday to agree to continue supportive measures for the global economy and look to boost the International Monetary Fund’s resources so it can help poorer countries fight off the effects of the pandemic.

Finance ministers and central bank governors of the world’s top 20 economies, called the G20, held a video-conference on Friday. The global response to the economic havoc wreaked by the coronavirus was at top of the agenda.

In the first comments by a participating policymaker, the European Union’s economics commissioner Paolo Gentiloni said the meeting had been “good,” with consensus on the need for a common effort on global COVID vaccinations.

“Avoid premature withdrawal of supportive fiscal policy” and “progress towards agreement on digital and minimal taxation” he said in a Tweet, signaling other areas of apparent accord.

A news conference by Italy, which holds the annual G20 presidency, is scheduled for 17.15  (1615 GMT).

The meeting comes as the United States is readying $1.9 trillion in fiscal stimulus and the European Union has already put together more than 3 trillion euros ($3.63 trillion) to keep its economies going despite COVID-19 lockdowns.

But despite the large sums, problems with the global rollout of vaccines and the emergence of new variants of the coronavirus mean the future of the recovery remains uncertain.

German Finance Minister Olaf Scholz warned earlier on Friday that recovery was taking longer than expected and it was too early to roll back support.

“Contrary to what had been hoped for, we cannot speak of a full recovery yet. For us in the G20 talks, the central task remains to lead our countries through the severe crisis,” Scholz told reporters ahead of the virtual meeting.

“We must not scale back the support programs too early and too quickly. That’s what I’m also going to campaign for among my G20 colleagues today,” he said.

BIDEN DEBUT

Hopes for constructive discussions at the meeting are high among G20 countries because it is the first since Joe Biden, who vowed to rebuild cooperation in international bodies, became U.S. president.

While the IMF sees the U.S. economy returning to pre-crisis levels at the end of this year, it may take Europe until the middle of 2022 to reach that point.

The recovery is fragile elsewhere too – factory activity in China grew at the slowest pace in five months in January, hit by a wave of domestic coronavirus infections, and in Japan fourth quarter growth slowed from the previous quarter with new lockdowns clouding the outlook.

“The initially hoped-for V-shaped recovery is now increasingly looking rather more like a long U-shaped recovery. That is why the stabilization measures in almost all G20 states have to be maintained in order to continue supporting the economy,” a G20 official said.

But while the richest economies can afford to stimulate an economic recovery by borrowing more on the market, poorer ones would benefit from being able to tap credit lines from the IMF — the global lender of last resort.

To give itself more firepower, the Fund proposed last year to increase its war chest by $500 billion in the IMF’s own currency called the Special Drawing Rights (SDR), but the idea was blocked by then U.S. President Donald Trump.

Scholz said the change of administration in Washington on Jan. 20 improved the prospects for more IMF resources. He pointed to a letter sent by U.S. Treasury Secretary Janet Yellen to G20 colleagues on Thursday, which he described as a positive sign also for efforts to reform global tax rules.

Civil society groups, religious leaders and some Democratic lawmakers in the U.S. Congress have called for a much larger allocation of IMF resources, of $3 trillion, but sources familiar with the matter said they viewed such a large move as unlikely for now.

The G20 may also agree to extend a suspension of debt servicing for poorest countries by another six months.

($1 = 0.8254 euros)

(Reporting by Michael Nienaber in Berlin, Jan Strupczewski in Brussels and Gavin Jones in Rome; Andrea Shalal and David Lawder in Washington; Editing by Daniel Wallis, Susan Fenton and Crispian Balmer)

U.S. urban office market, stung by pandemic, hopes tech firms drive comeback

By Herbert Lash

NEW YORK (Reuters) – The growing footprint in New York of major tech companies like Amazon.com Inc, Facebook Inc and Alphabet Inc’s Google has given property owners and brokers hope that once the coronavirus has been conquered demand for office space will quickly return to pre-pandemic levels.

But the popularity of working from home and the exodus of people from expensive coastal cities will likely weigh on demand and change workspace requirements, leaving office buildings that do not adjust less valuable.

Big Tech’s expanding real estate clout already hides declining values for lower-quality properties.

Prices for premier workspace in U.S. gateway cities have held or even risen during the pandemic in a flight to quality. But leasing volumes and number of buildings sold have plummeted, with valuations at the lower end falling, data shows.

The pandemic has left a massive question mark hanging over the office sector, said Joe Gorin, head of U.S. real estate management and value-added investing at Barings in New York.

“I know how people are going to use the hotel coming out of the pandemic. How are people going to use office buildings?” he asked. “There’s going to be some pain because we’re going to have to go through a restructuring of how people use space.”

Companies need to make the office more compelling and allow busy work to be done at home, which means workspace demand might not grow, Gorin said. Buildings that cannot provide a great environment will become obsolete.

“If you can own or create the right stuff, it’s going to be valuable,” he said. “Office can become more important and shrink as much as it can expand.”

Limited data suggests buildings classified below the top Class A industry designation already have suffered a drop in value during the pandemic and could be poised for a further slide if a decline in demand persists.

The amount of available office space has soared as tech companies have dumped excessive workspace, a sign of uncertainty among management about a company’s future workspace needs.

Institutional investors have put transaction decisions on hold, with the sale of buildings in Manhattan valued at more than $100 million falling more than half to just 32 last year, research by brokerage Newmark Group Inc shows, using Real Capital Analytics data.

Leasing activity has picked up after the New Year but is still far below pre-pandemic levels.

The office sector is the hardest in commercial real estate to assess because leases generally are long-term commitments, said Sam Isaacson, president of Walker & Dunlop Investment Partners in Denver.

“Eventually the cash flow streams have to match up with the asset value appreciation and when that doesn’t occur, that’s when we’re going to see some real pain,” Isaacson said.

WAITING TO MEET THE BOSS

The number of virtual tours brokers conducted with clients fell 61% in December from a year earlier in seven U.S. gateway cities, according to data from View The Space Inc. Tours declined 74% in New York, the biggest drop outside of an 80% plunge in Seattle, the property technology firm said.

A reversal of Seattle’s early recovery from the pandemic may suggest a significant embrace of more remote work in the city over the long-term, VTS said in the report.

“Our data is pointing to the fact tech companies are still really comfortable working from home and they’re probably going to be the last ones to return to the office,” said Ryan Masiello, co-founder and chief strategy officer at VTS.

Of the 115 people VTS has hired since March, Masiello has met none of them because they are all working remotely, he said.

Tech companies led other industries for the second straight year in Manhattan leasing activity, brokerage CBRE Group Inc said in January. A decline in the technology sector’s real estate footprint would be significant for a property market looking to ride the growing digital economy.

Brokers point to Amazon’s $978 million purchase of the Lord & Taylor building on Fifth Avenue last year and Facebook’s leasing of the Farley Building across from Madison Square Garden, as prime examples for Manhattan’s real estate prospects.

The Amazon deal was valued at $1,466 a square foot, more than 10% above last year’s top-quartile average price, while Google’s billion-dollar deals in Chelsea and Hudson Square have redefined swaths of the city’s Far West Side.

Scott Rechler, chief executive and chairman of closely held RXR Realty, one of the largest office building owners in New York, sees a growing disparity between high- and lower-quality properties.

Companies need to re-imagine the workspace and how they engage with employees who expect properties to be well-located, energetic and have health and wellness centers, he said.

“For buildings that can’t do that – they’re not in the right location, they’re older, they’re obsolete – it could be a meaningful free-fall in value,” Rechler said.

(Reporting by Herbert Lash in New York; Editing by Alden Bentley and Matthew Lewis)

FDA advisory panel to review Johnson & Johnson COVID-19 vaccine with thumbs up expected

By Manas Mishra and Michael Erman

(Reuters) – A panel of expert advisers to the U.S. Food and Drug Administration began a meeting to discuss Johnson & Johnson’s one-dose COVID-19 vaccine on Friday, setting the stage for a possible emergency use authorization as early as this week.

After it receives the recommendation, the FDA is likely to authorize the vaccine for emergency use within a day or so, making it the third available in the United States, and the only one that requires just one shot.

The panel, consisting of doctors, infectious disease experts and medical researchers, began the meeting at 9:00 a.m. ET (1400 GMT), and will vote in favor or against the vaccine’s use several hours later at the end of the meeting.

The panel will consider whether the benefits of the vaccine outweigh its risk for use in people aged 18 and older.

In a 44,000-person trial, the vaccine overall was 66% effective at preventing moderate-to-severe cases of COVID-19 compared with a placebo.

The effectiveness of the one-dose vaccine varied over time and location. In the United States, the effectiveness was 74% at 14 days and 72% two weeks later, while the shot was 64% effective at stopping moderate-to-severe COVID-19 after 28 days in South Africa, where a worrying new variant has swept across the country.

The vaccine was 100% effective at preventing hospitalizations 28 days after vaccination and there were no COVID-19 deaths among those who received the shot.

“In the context of the pandemic, the FDA is likely to issue an emergency use authorization (EUA) based on the data,” said UBS analyst Navin Jacob ahead of the panel meeting.

The J&J vaccine can be stored in normal refrigerator temperatures, making distribution easier than that of the Pfizer Inc/BioNTech SE and Moderna Inc vaccines that use mRNA technology and must be shipped and stored frozen.

J&J’s vaccine uses a common cold virus known as adenovirus type 26 to introduce coronavirus proteins into cells in the body and trigger an immune response.

Three to four million doses of the vaccine are expected to be rolled out next week.

(Reporting by Manas Mishra in Bengaluru and Michael Erman in New York; Editing by Caroline Humer, Bill Berkrot and Shounak Dasgupta)

U.S. CDC says trend of decline in COVID-19 cases may be stalling

WASHINGTON (Reuters) – The head of the U.S. Centers for Disease Control and Prevention said on Friday that a recent decline in COVID-19 cases may be stalling, a development she described as concerning while urging that restrictions to fight the virus remain in place.

Dr. Rochelle Walensky told reporters the CDC was watching the concerning data closely.

The White House on Friday also urged companies to join efforts to help fight the pandemic by requiring mask wearing by employees and educating customers.

Andy Slavitt, a senior adviser on the White House’s COVID-19 response team, listed a number of companies that were taking measures to help with the pandemic fight and urged more to join.

Ford and the Gap were producing and donating millions of masks, he said, while Best Buy, Target and Dollar General were giving workers paid time off to get vaccines.

The White House is working on a broad campaign to educate Americans about the vaccine as it seeks to bring the pandemic that has killed more than 500,000 people in the United States under control.

President Joe Biden on Thursday noted concerns that later this spring supply of the vaccines would outstrip demand because of vaccine hesitancy.

(Reporting by Jeff Mason, Carl O’Donnell and Lisa Lambert; Editing by Chizu Nomiyama)

U.S. to buy at least 100,000 doses of Lilly’s COVID-19 antibody therapy

(Reuters) – Drugmaker Eli Lilly and Co said on Friday the U.S. government has agreed to buy at least 100,000 doses of its newly authorized COVID-19 dual antibody cocktail for $210 million, with doses to be delivered through March-end.

The U.S. government will have the option to purchase up to an additional 1.1 million doses through Nov. 25, the company said.

Lilly said it would begin shipping these doses immediately.

The therapy contains two antibodies bamlanivimab and etesevimab and had got U.S. emergency use authorization earlier this month.

Like rival Regeneron Pharmaceuticals Inc’s dual antibody therapy REGN-COV2, Lilly’s combo has been authorized for the treatment of mild to moderate COVID-19 in patients who are at high risk of progressing to severe disease or hospitalization.

Lilly’s therapy helped cut the risk of hospitalization and death in COVID-19 patients by 70%, according to early late-stage trial data put out in January.

Despite the government’s efforts to encourage use of the treatments to help keep people out of hospitals, the therapies have seen weak demand.

Healthcare systems have said they have been slow to ramp up use of the antibodies due to extra levels of complexity during the pandemic, including requirements for quick diagnosis times and the need to isolate infectious patients.

United States had already agreed to buy 1.45 million doses of bamlanivimab alone, Lilly said, adding that 1 million of doses have already been delivered and 450,000 additional doses will be delivered by March-end.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shounak Dasgupta)

Debilitating ‘long-COVID’ may have severe health, social impacts: WHO

By Kate Kelland

LONDON (Reuters) – Thousands of COVID-19 patients continue to suffer serious, debilitating and lingering symptoms many months after their initial bout of infection, with major social, health and economic consequences, European health experts said on Thursday.

Publishing a World Health Organization-led guidance report on the condition, often referred to as “long COVID” or “post-COVID syndrome,” experts said around one in 10 COVID-19 patients are still unwell 12 weeks after their acute infection, and many suffer symptoms for far longer.

“This is a condition that can be extremely debilitating. Those suffering from it describe a varying combination of overlapping symptoms… (including) chest and muscle pain, fatigue, shortness of breath … brain fog (and) many others,” said Martin McKee, a professor at the European Observatory on Health Systems and Policies who led the report.

Hans Kluge, the WHO’s European regional director, said long-COVID could have “severe social, economic, health and occupational consequences.”

“The burden is real and it is significant,” he said.

He urged health authorities to listen to patients’ concerns, take them seriously, and establish services to help them.

Growing evidence from around the world points to many thousands of people experiencing long-COVID. The condition appears not to be linked to whether a patient had a severe or mild infection.

An initial report by Britain’s National Institute for Health Research last year suggested long-COVID may be not one condition, but multiple syndromes causing a rollercoaster of symptoms affecting the body and mind.

Kluge noted that as with any new disease, much remains unknown about COVID-19.

“We need to listen and … understand. The sufferers of post-COVID conditions need to be heard if we are to understand the long-term consequences and recovery from COVID-19,” he said. “This is a clear priority for WHO (and) it should be for every health authority.”